Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathrin Reetz

Showing results (161-170 of 196) with videos related to

Pageof 20
Sort By:
Journal of Neurology|April 17, 2025
Optimizing selectivity of the Cerebellar Cognitive Affective Syndrome Scale by use of correction formulas, and validation of its German versionAndreas Thieme, Kerstin Rubarth, Raquel van der Veen, et al.
The Lancet Regional Health. Europe|January 5, 2026
Patient-reported, psychosocial and health economic outcomes in mild to moderate Friedreich's ataxia: baseline results of the PROFA studyMarcus Grobe-Einsler, Stéphanie Borel, Maresa Buchholz, et al.
The Lancet. Neurology|May 28, 2013
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline dataHeike Jacobi, Kathrin Reetz, Sophie Tezenas du Montcel, et al.
The Lancet. Neurology|August 22, 2020
Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort studyHeike Jacobi, Sophie Tezenas du Montcel, Sandro Romanzetti, et al.
Journal of Neurology|November 3, 2022
The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factorsHolger Hengel, Peter Martus, Jennifer Faber, et al.
Neuropathology and Applied Neurobiology|February 17, 2023
A standardised protocol for blood and cerebrospinal fluid collection and processing for biomarker research in ataxiaMagda M Santana, Laetitia S Gaspar, Maria M Pinto, et al.
EMBO Molecular Medicine|June 9, 2020
Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and miceCarlo Wilke, Eva Haas, Kathrin Reetz, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|September 20, 2021
Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessmentsAnja Ophey, Steffen Wolfsgruber, Sandra Roeske, et al.
Parkinsonism & Related Disorders|June 21, 2016
Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's diseaseDavid Mengel, Judith Dams, Jannis Ziemek, et al.
Disease Models & Mechanisms|January 22, 2017
Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's diseaseSuna Lahut, Suzana Gispert, Özgür Ömür, et al.
Pageof 20

Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
Journal of Neurology|April 17, 2025
Optimizing selectivity of the Cerebellar Cognitive Affective Syndrome Scale by use of correction formulas, and validation of its German versionAndreas Thieme, Kerstin Rubarth, Raquel van der Veen, et al.
The Lancet Regional Health. Europe|January 5, 2026
Patient-reported, psychosocial and health economic outcomes in mild to moderate Friedreich's ataxia: baseline results of the PROFA studyMarcus Grobe-Einsler, Stéphanie Borel, Maresa Buchholz, et al.
The Lancet. Neurology|May 28, 2013
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline dataHeike Jacobi, Kathrin Reetz, Sophie Tezenas du Montcel, et al.
The Lancet. Neurology|August 22, 2020
Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort studyHeike Jacobi, Sophie Tezenas du Montcel, Sandro Romanzetti, et al.
Journal of Neurology|November 3, 2022
The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factorsHolger Hengel, Peter Martus, Jennifer Faber, et al.
Neuropathology and Applied Neurobiology|February 17, 2023
A standardised protocol for blood and cerebrospinal fluid collection and processing for biomarker research in ataxiaMagda M Santana, Laetitia S Gaspar, Maria M Pinto, et al.
EMBO Molecular Medicine|June 9, 2020
Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and miceCarlo Wilke, Eva Haas, Kathrin Reetz, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|September 20, 2021
Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessmentsAnja Ophey, Steffen Wolfsgruber, Sandra Roeske, et al.
Parkinsonism & Related Disorders|June 21, 2016
Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's diseaseDavid Mengel, Judith Dams, Jannis Ziemek, et al.
Disease Models & Mechanisms|January 22, 2017
Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's diseaseSuna Lahut, Suzana Gispert, Özgür Ömür, et al.
Pageof 20